中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 4
Apr.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(4): 840-847

Association between triglyceride glucose-body mass index and new-onset metabolic dysfunction-associated fatty liver disease

DOI: 10.12449/JCH260412
  • 1.

    Preventive Medicine and Physical Examination Center，The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University，Luzhou，Sichuan 646000，China

  • 2.

    Department of Hepatology，The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University，Luzhou，Sichuan 646000，China

Research funding:

Joint Project of Luzhou Municipal People’s Government and Southwest Medical University (2023LZXNYDj027);

Joint Project of Southwest Medical University-The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University (2020XYLH-071)

More Information
  • Corresponding author: HUANG Suqiong， 872165173@qq.com （ORCID： 0009-0004-5272-7700）
  • Received Date: 2025-10-29
  • Accepted Date: 2026-02-10
  • Published Date: 2026-04-25
    Abstract
  •   Objective  To investigate the association between serum fasting triglyceride glucose-body mass index （TyG-BMI） and new-onset metabolic dysfunction-associated fatty liver disease （MAFLD） within 10 years.  Methods  A retrospective analysis was performed for the data of individuals who underwent physical examination in The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University in 2013， 2018， and 2023 and were not diagnosed with MAFLD in 2013， and a total of 1 340 valid subjects were enrolled according to the inclusion and exclusion criteria. The gbmt package in R 4.3.0 was used to construct the dynamic change trajectory model of TyG-BMI， and four different TyG-BMI trajectory groups were determined， i.e.， the low-level group （n=352）， the medium-level group （n=517）， the high-level group （n=314）， and the extremely high-level group （n=157）. The data on general information and blood biochemical parameters were collected from all subjects and were then compared between groups. The chi-square test was used for comparison of categorical data between groups， and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data with heterogeneity of variance between multiple groups. The Cox regression analysis was used to investigate the association between different TyG-BMI trajectories and the risk of MAFLD， and the receiver operating characteristic （ROC） curve was used to assess the value of TyG-BMI in the diagnosis of MAFLD.  Results  The cumulative incidence rate of MAFLD increased with the increase in the level of TyG-BMI trajectory， with a cumulative incidence rate of 4.83% in the low-level group， 29.98% in the medium-level group， 61.15% in the high-level group， and 83.44% in the extremely high-level group （P<0.001）， and the cumulative incidence rate of MAFLD in men was significantly higher than that in women （51.34% vs 20.67%， P<0.001）. The multivariate Cox regression analysis showed that increases in the levels of TyG-BMI trajectory， uric acid， diastolic blood pressure， hemoglobin， and alanine aminotransferase were independent risk factors for the onset of MAFLD （all P<0.05）， while the increase in high-density lipoprotein cholesterol was an independent protective factor against MAFLD （P<0.001）. After adjustment for confounding factors， the medium-， high-， and extremely high-level groups had a hazard ratio of 4.430 （95% confidence interval ［CI］： 2.660 — 7.377， P<0.001）， 6.937 （95%CI： 4.110 — 11.708， P<0.001）， and 7.989 （95%CI： 4.616 — 13.827， P<0.001）， respectively. The ROC curve analysis showed that TyG-BMI had the highest diagnostic value， with an area under the ROC curve of 0.859 （95%CI： 0.840 — 0.879）， a sensitivity of 79.8%， and a specificity of 76.3%.  Conclusion  The risk of MAFLD increases with the increase in the level of TyG-BMI trajectory， and TyG-BMI can be used as a predictive indicator for MAFLD.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    GUO XY, YIN XZ, LIU ZJ, et al. Non-alcoholic fatty liver disease(NAFLD) pathogenesis and natural products for prevention and treatment[J]. Int J Mol Sci, 2022, 23( 24): 15489. DOI: 10.3390/ijms232415489.
    [2]
    HUANG WS. The prevalence of metabolic dysfunction-associated fatty liver disease in Asia[J]. J Clin Hepatol, 2025, 41( 9): 1721- 1724. DOI: 10.12449/JCH250901.

    黄炜燊. 亚洲地区代谢相关脂肪性肝病流行情况[J]. 临床肝胆病杂志, 2025, 41( 9): 1721- 1724. DOI: 10.12449/JCH250901.
    [3]
    ESLAM M, SANYAL AJ, GEORGE J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158( 7): 1999- 2014. DOI: 10.1053/j.gastro.2019.11.312.
    [4]
    ESLAM M, FAN JG, YU ML, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int, 2025, 19( 2): 261- 301. DOI: 10.1007/s12072-024-10774-3.
    [5]
    TANASE DM, GOSAV EM, COSTEA CF, et al. The intricate relationship between type 2 diabetes mellitus(T2DM), insulin resistance(IR), and nonalcoholic fatty liver disease(NAFLD)[J]. J Diabetes Res, 2020, 2020: 3920196. DOI: 10.1155/2020/3920196.
    [6]
    YANG B, ZHANG R. Progress on the treatment of metabolic associated fatty liver disease[J/OL]. Chin J Liver Dis(Electronic Version), 2024, 16( 4): 25- 30. DOI: 10.3969/j.issn.1674-7380.2024.04.004.

    杨彬, 张瑞. 代谢相关脂肪性肝病治疗进展[J/OL]. 中国肝脏病杂志(电子版), 2024, 16( 4): 25- 30. DOI: 10.3969/j.issn.1674-7380.2024.04.004.
    [7]
    FERGUSON D, FINCK BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2021, 17( 8): 484- 495. DOI: 10.1038/s41574-021-00507-z.
    [8]
    XUE Y, XU JH, LI M, et al. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters[J]. Front Endocrinol, 2022, 13: 951689. DOI: 10.3389/fendo.2022.951689.
    [9]
    MIN Y, WEI XY, WEI ZG, et al. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease[J]. Cardiovasc Diabetol, 2024, 23( 1): 188. DOI: 10.1186/s12933-024-02287-y.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.

    中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
    [11]
    LEI RY, XUE BD, TIAN XY, et al. The association between endocrine disrupting chemicals and MAFLD: Evidence from NHANES survey[J]. Ecotoxicol Environ Saf, 2023, 256: 114836. DOI: 10.1016/j.ecoenv.2023.114836.
    [12]
    CHEN N, GENG N, LI J. Mechanisms and clinical practice advances in weight reduction for patients with metabolic associated fatty liver disease[J/OL]. Chin J Liver Dis(Electronic Version), 2025, 17( 3): 10- 16. DOI: 10.3969/j.issn.1674-7380.2025.03.002.

    陈楠, 耿楠, 李婕. 代谢相关脂肪性肝病患者减重治疗机制与临床实践进展[J/OL]. 中国肝脏病杂志(电子版), 2025, 17( 3): 10- 16. DOI: 10.3969/j.issn.1674-7380.2025.03.002.
    [13]
    PETTA S, DI MARCO V, PIPITONE RM, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population[J]. Liver Int, 2018, 38( 11): 2060- 2068. DOI: 10.1111/liv.13743.
    [14]
    RUBINO F, CUMMINGS DE, ECKEL RH, et al. Definition and diagnostic criteria of clinical obesity[J]. Lancet Diabetes Endocrinol, 2025, 13( 3): 221- 262. DOI: 10.1016/S2213-8587(24)00316-4.
    [15]
    ER LK, WU S, CHOU HH, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals[J]. PLoS One, 2016, 11( 3): e0149731. DOI: 10.1371/journal.pone.0149731.
    [16]
    TAO LC, XU JN, WANG TT, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: Landscape and limitations[J]. Cardiovasc Diabetol, 2022, 21( 1): 68. DOI: 10.1186/s12933-022-01511-x.
    [17]
    ZHOU JH, ZHOU F, WANG WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71( 5): 1851- 1864. DOI: 10.1002/hep.31150.
    [18]
    QIN Q, ZHANG T, YAN S, et al. The reliation between trajectory of triglyceride glucose index combined with body mass index and new-onset non-alcoholic fatty liver disease[J]. Chin Health Manag, 2023, 17( 12): 909- 915. DOI: 10.3760/cma.j.cn115624-20230720-00020.

    秦迁, 张滔, 闫肃, 等. 甘油三酯葡萄糖指数联合体重指数的轨迹与新发非酒精性脂肪性肝病的相关性[J]. 中华健康管理学杂志, 2023, 17( 12): 909- 915. DOI: 10.3760/cma.j.cn115624-20230720-00020.
    [19]
    TONG C, LI Q, KONG L, et al. Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence[J]. J Endocrinol Invest, 2022, 45( 12): 2233- 2245. DOI: 10.1007/s40618-022-01848-w.
    [20]
    CHEN Q, YANG LY, ZHANG JX, et al. Correlation of non-alcoholic fatty liver with blood lipids and blood routine indicators[J]. Int Med Health Guid News, 2019, 25( 11): 1810- 1813. DOI: 10.3760/cma.j.issn.1007-1245.2019.11.040.

    陈群, 杨柳茵, 张建兴, 等. 非酒精性脂肪肝与血脂及血常规指标的相关性[J]. 国际医药卫生导报, 2019, 25( 11): 1810- 1813. DOI: 10.3760/cma.j.issn.1007-1245.2019.11.040.
    [21]
    WANG S, ZHANG J, ZHANG J, et al. A cohort study on the correlation between body mass index trajectories and new-onset non-alcoholic fatty liver disease[J]. Chin J Hepatol, 2020, 28( 7): 597- 602. DOI: 10.3760/cma.j.cn501113-20190629-00230.

    王珊, 张健, 张杰, 等. 体质量指数轨迹与新发非酒精性脂肪性肝病相关性的队列研究[J]. 中华肝脏病杂志, 2020, 28( 7): 597- 602. DOI: 10.3760/cma.j.cn501113-20190629-00230.
    [22]
    WANG LN, GAO PF, CAO F, et al. Analysis of the prevalence and influencing factors of non-alcoholic fatty liver disease in different gender groups[J]. Chin Gen Pract, 2023, 26( 33): 4143- 4151. DOI: 10.12114/j.issn.1007-9572.2023.0107.

    王丽娜, 高鹏飞, 曹帆, 等. 不同性别人群非酒精性脂肪性肝病患病现况及影响因素分析[J]. 中国全科医学, 2023, 26( 33): 4143- 4151. DOI: 10.12114/j.issn.1007-9572.2023.0107.
    [23]
    LI YW, SHAN LL, WEN Q, et al. Triglyceride glucose-waist circumference as a useful predictor for diabetes mellitus: A secondary retrospective analysis utilizing a Japanese cohort study[J]. BMC Endocr Disord, 2025, 25( 1): 17. DOI: 10.1186/s12902-025-01834-2.
    [24]
    JIANG CY, YANG RJ, KUANG MB, et al. Triglyceride glucose-body mass index in identifying high-risk groups of pre-diabetes[J]. Lipds Health Dis, 2021, 20( 1): 161. DOI: 10.1186/s12944-021-01594-7.
    [25]
    SHENG GT, LU S, XIE QY, et al. The usefulness of obesity and lipid-related indices to predict the presence of non-alcoholic fatty liver disease[J]. Lipids Health Dis, 2021, 20( 1): 134. DOI: 10.1186/s12944-021-01561-2.
    [26]
    ZHANG Q, LIU ZL, ZHANG JQ, et al. Association between TyG related parameters and metabolic dysfunction associated fatty liver disease among nondiabetic individuals[J]. Sci Rep, 2025, 15( 1): 4566. DOI: 10.1038/s41598-024-84917-9.
    [27]
    HU HF, HAN Y, CAO CC, et al. The triglyceride glucose-body mass index: A non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population[J]. J Transl Med, 2022, 20( 1): 398. DOI: 10.1186/s12967-022-03611-4.
    [28]
    CHEN QL, HU PP, HOU XX, et al. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease[J]. Cardiovasc Diabetol, 2024, 23( 1): 232. DOI: 10.1186/s12933-024-02343-7.
    [29]
    SON DH, LEE HS, LEE YJ, et al. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome[J]. Nutr Metab Cardiovasc Dis, 2022, 32( 3): 596- 604. DOI: 10.1016/j.numecd.2021.11.017.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (42) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return